ImmuPharma (LON:IMM) Shares Down 1.5% – Here’s Why

ImmuPharma plc (LON:IMM)’s share price dropped 1.5% during trading on Monday . The stock traded as low as GBX 2.93 ($0.04) and last traded at GBX 3.06 ($0.04). Approximately 1,581,628 shares traded hands during trading, a decline of 82% from the average daily volume of 8,777,133 shares. The stock had previously closed at GBX 3.11 ($0.04).

ImmuPharma Price Performance

The firm has a market cap of £13.02 million, a PE ratio of -5.30 and a beta of 1.53. The firm has a 50-day simple moving average of GBX 2.91 and a 200 day simple moving average of GBX 2.72.

ImmuPharma (LON:IMM) last posted its quarterly earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.